Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service prostatectomy & nephrectomy cases in New York: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (203 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 39 | 2,565 | 46% |
| 2020 | 31 | 2,066 | 48% |
| 2021 | 40 | 2,372 | 51% |
| 2022 | 36 | 2,246 | 53% |
| 2023 | 30 | 2,262 | 55% |
| 2024 | 33 | 2,271 | 57% |
| 2025 from claims | – | 2,525 2,317–2,671 | 58% |
| 2026 forecast | – | 2,570 2,262–2,966 | 58% |
| 2027 forecast | – | 2,605 2,227–3,104 | 59% |
| 2028 forecast | – | 2,640 2,203–3,232 | 59% |
| 2029 forecast | – | 2,674 2,184–3,354 | 60% |
| 2030 forecast | – | 2,709 2,170–3,471 | 60% |
Robotic radical prostatectomy and laparoscopic nephrectomy. Professional codes (what the surgeon bills): CPT 55866, 50543, 50545, 50546, 50548; the hospital bills MS-DRG 707, 708, 656, 657, 658.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 53% of the cases CMS names in New York; 20 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 58% inpatient hospital, 42% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~2,600 | ~1,500 | ~1,100 |
| 2027 · ~2,600 | ~1,500 | ~1,200 |
| 2028 · ~2,600 | ~1,500 | ~1,200 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 45% (42% in 2025), inpatient hospital about 55% (58% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 27 | 1,659−0.2%/yr | −0.2%/yr | 1.3 | 0% | 1,900 in 2030+2.3%/yr |
| Massachusetts | 10 | 885−2.7%/yr | −2.7%/yr | 1.0 | 0% | 1,070 in 2030+3.2%/yr |
| New Jersey | 9 | 867+0.5%/yr | +0.5%/yr | 0.9 | 0% | 1,060 in 2030+3.4%/yr |
| Connecticut | 4 | 324+1.3%/yr | +1.3%/yr | 1.1 | 0% | 480 in 2030+6.6%/yr |
| New Hampshire | 5 | 194−3.3%/yr | −3.3%/yr | 0.9 | 0% | 300 in 2030+7.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 98 | 8,386−6.8%/yr | −6.8%/yr | 4.61.1× | 43% | 8,420 in 2030+0.1%/yr |
| Kidney stone management | 134 | 7,123−2.3%/yr | −2.3%/yr | 4.00.6× | 10% | 7,020 in 2030−0.2%/yr |
| Hysterectomy, hysteroscopy & ablation | 75 | 6,108−0.3%/yr | −0.3%/yr | 3.71.1× | 30% | 6,960 in 2030+2.2%/yr |
| Incontinence, prolapse & sacral neuromodulation | 38 | 3,138−0.8%/yr | −0.8%/yr | 1.70.9× | 8% | 3,860 in 2030+3.5%/yr |
Prostatectomy & nephrectomy in every state, and its device makers · Every procedure market in New York · Every state · Compare with Pennsylvania
Intuitive Surgical leads with 98% of company spending on these surgeons in 2025, level with 2024.
In 2025, 4 companies reported engagement with New York’s surgeons worth $467K in consulting, speaking, meals and travel tied to these products, about $14K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 9 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
New York’s own discharge file counts every inpatient stay, whatever the payer: 6,455 prostatectomy and nephrectomy stays at 64 hospitals in 2024, against the Medicare-only figures above. The most commercial of the busy ones is MOUNT SINAI WEST (54% commercial): where commercial rates leave the most room for a premium product.
| Hospital | Cases | Medicare | Commercial |
|---|---|---|---|
| MOUNT SINAI HOSPITAL NEW YORK | 863 | 37% | 52% |
| NYU LANGONE HOSPITALS NEW YORK | 587 | 39% | 50% |
| MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES NEW YORK | 373 | 40% | 50% |
| NEW YORK-PRESBYTERIAN HOSPITAL NEW YORK | 353 | 45% | 43% |
| LONG ISLAND JEWISH MEDICAL CENTER NEW HYDE PARK | 351 | 42% | 41% |
| MONTEFIORE MEDICAL CENTER BRONX | 279 | 46% | 28% |
| MOUNT SINAI WEST NEW YORK | 235 | 44% | 54% |
| ROCHESTER GENERAL HOSPITAL ROCHESTER | 204 | 60% | 30% |
New York only: MedaRep has no other state’s all-payer file yet. Counted by principal procedure (Prostatectomy and nephrectomy). Medicare here includes Medicare Advantage. A hospital with 10 or fewer such stays, or a payer share of 10 or fewer, is not shown. Source: New York State Department of Health, SPARCS de-identified inpatient discharges (health.data.ny.gov). The New York State Department of Health makes no representation, warranty or guarantee relating to the data or analyses derived from these data. Accessed 2026-11-11.